Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

OncoTherapy Science Inc announces progress of phase III clinical trial of the peptide cocktail vaccine for patients with pancreatic cancer


Friday, 20 Dec 2013 07:00am EST 

OncoTherapy Science Inc:Says the current state of phase III clinical trial (COMPETE-PC Study (COMbined PEptide ThErapy for Pancreatic Cancer)) using the peptide cocktail vaccine 'C01.Says the Independent Data-Monitoring Committee has recommended that COMPETE-PC Study should be stopped because of the low probability of elongation of overall survival period in C01 group compared to the placebo group, at the third interim analysis.Says it has decided to stop the study. 

Company Quote

183.0
12.0 +7.02%
23 Jul 2014